GLP-1 Medications Just Got a Lot More Interesting

A study published last month in Annals of Oncology followed over 160,000 adults with obesity and no diabetes. One group took GLP-1 medications like semaglutide or tirzepatide. The other group received diet and exercise counseling only. Researchers tracked who developed obesity-associated cancers over two years.

People on GLP-1 medications had a 41% lower incidence of obesity-related cancers.

Forty-one percent.

Take a breath and let that number register, because it is a big one. Obesity is already a recognized risk factor for 13 different cancer types: breast, colorectal, endometrial, kidney, pancreatic, thyroid, ovarian, esophageal, gastric, liver, gallbladder, multiple myeloma, and meningioma. Together, those cancers account for roughly 40% of all cancers diagnosed in high-income countries. These are not rare diagnoses. These are cancers that touch almost every family.

The largest risk reductions in this study appeared for multiple myeloma, pancreatic cancer, endometrial cancer, and colorectal cancer. Those are cancers with notoriously grim outcomes when caught late. The possibility that a medication already being used for weight management might meaningfully reduce their incidence is not a minor finding.

Men in the study saw an even larger benefit, with a 68% risk reduction. Researchers believe this may partly reflect adherence patterns. Women tend to experience more gastrointestinal side effects with GLP-1 medications, so men may have stayed on treatment more consistently and accumulated higher cumulative exposure. That is a hypothesis, not a confirmed mechanism, but it is worth tracking as more data accumulates.

Tirzepatide showed a larger risk reduction than semaglutide in this data. Read that carefully though, because the study was not designed as a head-to-head comparison. Tirzepatide is newer and was prescribed to a somewhat different patient population. Drawing firm conclusions from that comparison alone would be premature.

Something important about the findings for Black patients: the risk reduction for this group did not reach statistical significance. The researchers were candid about why, and I want to be equally direct. The subgroup was small. Structural inequity in healthcare affects who gets prescribed these medications, how consistently patients can access and afford them, and how long they remain on treatment. Drawing biological conclusions from a dataset with those confounders already embedded in it would not be good science. This question deserves its own focused research, and it is not getting enough of it.

This study is not a green light to prescribe GLP-1 medications for cancer prevention. That conclusion is not supported yet. What the data suggest is that for patients who already have obesity and are candidates for GLP-1 therapy for weight management, the benefits may extend well beyond what the scale shows.

My patients ask me whether GLP-1 medications are worth it. They worry about cost, about the injection, about what happens if they stop. My answer is always the same: let's talk about what you are actually managing. Obesity is not a willpower problem. It is a disease with downstream consequences: cardiovascular disease, metabolic dysfunction, joint deterioration, and yes, cancer risk. Treating obesity effectively means treating all of those risks at the same time. This study adds a significant new dimension to that conversation, and it changes how I explain the stakes to every patient I evaluate for weight management.

We do not yet fully understand the mechanism. It may be the weight loss itself. Excess adipose tissue drives chronic inflammation, disrupts hormone regulation, and creates conditions where cancer cells are more likely to take hold. Significant weight loss changes that biological environment. GLP-1 receptors are also expressed directly on some cancer cells, and early preclinical work suggests receptor activation may suppress those cells' ability to proliferate. The honest answer is that we do not know whether the benefit comes primarily from the weight loss, from a direct drug effect, or from both working together. Prospective trials need to answer that question.

What we do know is compelling enough that it changes the conversation. Treating obesity seriously is not about the number on a scale. It is about what that number represents for your long-term health, your disease risk, and the years you get to spend doing the things that matter to you. This is one more piece of evidence that getting it managed, and getting it managed well, is worth it.

The Easy Keeper is my physician-evaluated weight management program built around exactly this kind of care. Not a quick fix, not a prescription handed over without context. A real conversation about what your body is carrying, what it is at risk for, and how we work through it together. If this study made you think differently about where you are, that conversation starts at presencemd.net.

TL;DR on the Study

The basics: A large observational study examining whether GLP-1 receptor agonist medications reduce the risk of obesity-associated cancers in people without diabetes, published June 2026 in Annals of Oncology.

Who was in the study: 229,467 adults with obesity and no prior diabetes or obesity-associated cancer, drawn from the TriNetX federated database. After propensity score matching, 80,899 patients per group were compared. Mean age was 47; about 72% were women.

What they did: Researchers used a target trial emulation framework, which applies randomized trial structure to observational data. One group received at least two GLP-1 prescriptions, primarily semaglutide or tirzepatide. The comparison group received only diet and exercise counseling. Researchers tracked new cancer diagnoses over two years.

The results: GLP-1 users had a 41% lower incidence of obesity-associated cancers overall. Men saw a 68% risk reduction. Greatest risk reductions appeared for multiple myeloma, pancreatic cancer, endometrial cancer, and colorectal cancer. No significant risk reduction was found for breast cancer, ovarian cancer, or meningioma. The finding for Black patients did not reach statistical significance, though the subgroup was small.

Why it matters: Obesity drives 13 cancer types. If GLP-1 medications reduce that cancer risk even partially, the implications for how we think about obesity treatment extend well beyond metabolic health and the number on the scale.

The catch: This is observational data, not a randomized controlled trial. Causation cannot be confirmed. The tirzepatide versus semaglutide comparison was not the study's design intent and should not be over-interpreted. The lack of significant findings in Black patients most likely reflects access and adherence inequities rather than biology. Long-term prospective trials are needed before GLP-1s are recommended specifically for cancer prevention.

How it works (probably): Two leading theories. First, significant weight loss reduces chronic adipose-driven inflammation and hormone dysregulation that create a cancer-permissive environment. Second, GLP-1 receptors are expressed on some cancer cells directly, and receptor activation may suppress cancer cell proliferation. Most likely some combination of both mechanisms is at play.